Drug intelligence / Profile preview

AV-EC2023

Development stage: Unknown
Lead developer: A.Vogel
Administration: Oral

Overview

**AV-EC2023** is an investigational oral herbal medicinal product developed by A.Vogel for **insomnia in adults**. The tablet product contains *Eschscholzia californica* as its active botanical substance and has been evaluated in a Phase III randomized, placebo-controlled clinical trial. Its specific molecular pharmacology and direct biological target have not been publicly disclosed.

Other names: Escholzia tablets

Beyond the preview

Go deeper on AV-EC2023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV-EC2023.

Explore the full profile